RecruitingPhase 2NCT04316546

MK-7075 (Miransertib) in Proteus Syndrome

Studying Proteus syndrome

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Human Genome Research Institute (NHGRI)
Principal Investigator: Leslie G Biesecker, M.D., MD
National Human Genome Research Institute (NHGRI)
Intervention: MK-7075 (miransertib)(drug)
Enrollment: 45 enrolled
Eligibility: 3-99 years · All sexes
Timeline: 2022 – 2028

Study locations (1)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04316546 on ClinicalTrials.gov

Other trials for Proteus syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001403
Study of Proteus Syndrome and Related Congenital Disorders
National Human Genome Research Institute (NHGRI)

See all trials for Proteus syndrome →

← Back to all trials